TEM's Q3 Earnings & Revenues Beat, Stock Down in After-Market HoursZacks Investment Research • 11/05/25
Tempus Announces Six Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer Annual Meeting 2025Business Wire • 11/05/25
Tempus AI Enhances AI-Driven Diagnostics With Multiple FDA ApprovalsZacks Investment Research • 10/27/25
Tempus AI Stock Before Q3 Earnings Release: To Buy or Not to Buy?Zacks Investment Research • 10/20/25
Ambry Genetics Announces 10-Year Study in Genetics in Medicine Highlighting the Impact of Proactive Exome Reanalysis for Healthcare EquityBusiness Wire • 10/20/25
Tempus Announces Collaboration with Whitehawk Therapeutics to Advance Biomarker-Driven Oncology ResearchBusiness Wire • 10/16/25
Tempus Announces Six Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2025Business Wire • 10/15/25
Strategic Deals Drive TEM Growth Amid Competition: Buy, Hold or Sell?Zacks Investment Research • 10/09/25
Tempus Selected by ARPA-H to Provide CRO and Testing Services for the ADAPT Program, Advancing Precision Cancer TherapyBusiness Wire • 10/09/25